Reduction of subchondral bone marrow lesions concurrent with early recovery of trabecular bone mineral density in knee osteoarthritis following RANKL inhibitor administration for the treatment of osteoporosis: Implying human osteoporotic osteoarthritis?
Authors' conclusion
In this clinical study, after the application of a RANKL inhibitor for OP treatment, BMLs and knee pain were effectively reduced in OP patients with symptomatic KOA and BMLs. In addition, the correlation between early recovery of TBMD and reduction in BML area was also demonstrated.
Study context
- Population
- Osteoporosis (OP) patients with symptomatic knee OA and bone marrow lesions (BMLs), knee symptoms refractory to NSAID therapy
- Outcome
- Correlation between early TBMD recovery and BML reduction
- Follow-up
- 3 months
Methodological details6-month follow-up
- 6-month follow-up
Main finding
As reported in the abstract
Correlation of BML area reduction with CT-HU increase (positive), r
0.329
BML areas reduction, mm²
173.09 ± 45.23
CT-HU values increase
23.72 ± 3.77
Observational data: associations, not effects.
Further findings
Clinical symptoms and HRQoL · first week to final follow-up
- Clinical symptoms relieved from week 1, persisting to final follow-up; HRQoL improved
BMLs, trabecular bone mineral density (TBMD) and bone turnover markers · 4 weeks and 3 months
- BMLs and TBMD progressively improved; bone turnover markers significantly decreased
Systemic BMD · 6 months
- Systemic BMD improved
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →